Delving into the Latest Updates on GS-2121 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Gilead Sciences, Inc.

Active Organization

Gilead Sciences, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors.
The primary objectives of this study are:
* To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors.
* To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.

Start Date26 Jul 2024

Sponsor / Collaborator

Gilead Sciences, Inc.

100 Clinical Results associated with GS-2121

Login to view more data

100 Translational Medicine associated with GS-2121

Login to view more data

100 Patents (Medical) associated with GS-2121

Login to view more data

100 Deals associated with GS-2121

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	Canada	Gilead Sciences, Inc.	26 Jul 2024
Advanced Malignant Solid Neoplasm	Phase 1	United States	Gilead Sciences, Inc.	26 Jul 2024